FREE LIVE TRAINING
Psilocybin FDA Approval Is Coming: What It Means for Your Practice
Psilocybin could be FDA-approved as early as January 2027. Join Paul F. Austin for a clear update on approval, rescheduling, and access, and where you fit as a trained practitioner when demand outruns the clinics.
Paul F.
Austin
Paul F. Austin
Friday, November 6th
10 AM PT / 1 PM ET
Friday, November 6th at 10 AM PT / 1 PM ET
FDA Approval Is Close. The Clinics Won’t Keep Up.
In April, the FDA put psilocybin on a priority track that aims for a one- to two-month review.¹ Compass Pathways expects to launch in the first half of 2027.²
A senior adviser at the Department of Veterans Affairs (VA) says as many as 2.1 million veterans could benefit from psychedelic treatment, but admits, “Our demand will exceed our ability to supply these therapies, no doubt.”³ Since Oregon’s 2020 ballot measures, up to 90,000 more people a year use psilocybin,⁴ but the state’s legal program served fewer than 6,000 clients in 2025.⁵ And Compass’ treatment is drug-first, with no talk therapy built in.³
More people will try psychedelics than there are trained practitioners to support them. On November 6th, Paul will show you what’s coming, and where you fit.
What You'll Learn:
Where psilocybin’s FDA review stands now, and the realistic timeline from approval to the first patients
What REMS (the FDA’s safety program) and supervised-dosing rules are likely to require, and who will (and won’t) be allowed to deliver treatment
Cash pay vs. insurance: what treatment could cost patients at first (reportedly around $20,000 per dose⁶), and why high early costs could push demand outside the clinic
Why legal approval may drive a surge in use outside the medical system, and what Oregon’s data shows
What the VA’s push to treat veterans with psychedelics could mean for demand, and what’s next for MDMA-assisted therapy for PTSD, which could be approved as early as January 2027
Where trained practitioners fit in, inside clinics and out, and how to prepare your practice before demand peaks
Perfect For:
Perfect For:
Coaches & Wellness Practitioners
Clients are already asking you about psilocybin. You want to understand what approval means and how to support them safely, within your scope.
Clinicians & Therapists
You want a clear read on timelines, REMS, and reimbursement before approved treatments reach your patients, and on where non-clinical support fits alongside your care.
Psychedelic Guides & Facilitators
You already support people through psychedelic experiences. You want to know how approval and rescheduling could change demand, and what clients will expect from you.
Aspiring Practitioners
You’re considering psychedelic work as a career and want to know where demand is heading before you invest in training.
Your Host: Paul F. Austin
Your Host: Paul F. Austin
Paul F. Austin is an entrepreneur, coach, author, and pioneer in the psychedelic field, dedicated to bringing psychedelic education to the mainstream. As founder of Third Wave, he has empowered millions to have safe and meaningful psychedelic experiences, and his work has been featured in Bloomberg, Rolling Stone, Inc., and the BBC’s Worklife.
Paul treats psychedelic use as a refined skill, one cultivated through intention, mentorship, and courageous exploration. He founded the Psychedelic Coaching Institute to train the next generation of certified practitioners.
Paul treats psychedelic use as a refined skill, one cultivated through intention, mentorship, and courageous exploration. He founded the Psychedelic Coaching Institute to train the next generation of certified practitioners.
Live Q&A Session
Bring your biggest question about approval, access, or your own practice, and get it answered live by Paul.
ABOUT US
Why Learn From the Psychedelic Coaching Institute?
Now the gold standard in professional psychedelic training, we have taught hundreds of practitioners to master the skill of psychedelics since 2021.
Founder Paul F. Austin recognized a critical gap: more and more well-meaning people were interested in becoming practitioners, but few had the education, hands-on training, ethical clarity, and marketability to become credible and make a positive impact.
The Psychedelic Coaching Institute came into existence to close this gap by training the next generation of psychedelic leaders. We grew from our sister company, Third Wave, which has been a trusted resource for psychedelic education for 10+ years.
Today, we blend science, spirit, and skill to give our certified practitioners a comprehensive toolkit for preparation, facilitation, and integration. Paul’s expertise in intentional microdosing, in particular, guides many of our core methodologies.
We offer two flagship programs:
Rooted in a nervous system-first approach and equipped with entrepreneurial gusto, Psychedelic Coaching Institute practitioners are defining the future of this third wave of psychedelics.
Will you join us for this accessible entrance into your psychedelic career?
Founder Paul F. Austin recognized a critical gap: more and more well-meaning people were interested in becoming practitioners, but few had the education, hands-on training, ethical clarity, and marketability to become credible and make a positive impact.
The Psychedelic Coaching Institute came into existence to close this gap by training the next generation of psychedelic leaders. We grew from our sister company, Third Wave, which has been a trusted resource for psychedelic education for 10+ years.
Today, we blend science, spirit, and skill to give our certified practitioners a comprehensive toolkit for preparation, facilitation, and integration. Paul’s expertise in intentional microdosing, in particular, guides many of our core methodologies.
We offer two flagship programs:
- Practitioner Certification Program, a rigorous journey to psychedelic mastery
- Microdosing Practitioner Certification, an accessible entry point into psychedelic facilitation
Rooted in a nervous system-first approach and equipped with entrepreneurial gusto, Psychedelic Coaching Institute practitioners are defining the future of this third wave of psychedelics.
Will you join us for this accessible entrance into your psychedelic career?
¹ FDA National Priority Vouchers for psilocybin and methylone, April 24, 2026: https://krdo.com/news/2026/04/24/fda-moves-to-fast-track-review-of-psilocybin-and-methylone-for-mental-health/
² Compass Pathways Q2 2026 results (NDA completion expected Q4 2026, commercial launch expected first half of 2027): https://www.businesswire.com/news/home/20260805927238/en/Compass-Pathways-Announces-Second-Quarter-and-First-Half-2026-Financial-Results-and-Business-Highlights
³ Amanda Friedman, “The Trump administration moves to treat millions of mentally ill veterans with psychedelics,” POLITICO, October 25, 2026: https://www.politico.com/news/2026/10/25/trump-psychedelics-veterans-ptsd-01134515
⁴ Joshua C. Black et al., “Psilocybin Trends in States That Decriminalized Use,” JAMA, March 12, 2026: https://jamanetwork.com/journals/jama/fullarticle/2846422
⁵ Oregon Health Authority, Oregon Psilocybin Services 2025 Year-End Data Summary (5,935 clients served in 2025): https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/2025-Year-End-Data-Summary.pdf
⁶ Compass Pathways at the Deutsche Bank summit, September 17, 2026 (expected annual pricing around $50,000 to $65,000, priced per dose at the annual figure divided by three): https://www.investing.com/news/transcripts/compass-pathways-at-deutsche-bank-summit-launch-nears-for-comp360-93CH-4906106
² Compass Pathways Q2 2026 results (NDA completion expected Q4 2026, commercial launch expected first half of 2027): https://www.businesswire.com/news/home/20260805927238/en/Compass-Pathways-Announces-Second-Quarter-and-First-Half-2026-Financial-Results-and-Business-Highlights
³ Amanda Friedman, “The Trump administration moves to treat millions of mentally ill veterans with psychedelics,” POLITICO, October 25, 2026: https://www.politico.com/news/2026/10/25/trump-psychedelics-veterans-ptsd-01134515
⁴ Joshua C. Black et al., “Psilocybin Trends in States That Decriminalized Use,” JAMA, March 12, 2026: https://jamanetwork.com/journals/jama/fullarticle/2846422
⁵ Oregon Health Authority, Oregon Psilocybin Services 2025 Year-End Data Summary (5,935 clients served in 2025): https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/2025-Year-End-Data-Summary.pdf
⁶ Compass Pathways at the Deutsche Bank summit, September 17, 2026 (expected annual pricing around $50,000 to $65,000, priced per dose at the annual figure divided by three): https://www.investing.com/news/transcripts/compass-pathways-at-deutsche-bank-summit-launch-nears-for-comp360-93CH-4906106
